Exposure–Response Analyses for Upadacitinib Efficacy and Safety in the Crohn's Disease CELEST Study and Bridging to the Extended‐Release Formulation

Upadacitinib plasma concentrations, efficacy, and safety data from 216 subjects with moderate‐to‐severe active Crohn's disease (CD) from the 16‐week induction period of the CELEST study were analyzed to characterize upadacitinib exposure–response relationships in CD. Subjects in CELEST received...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed, Mohamed‐Eslam F., Klünder, Ben, Lacerda, Ana P., Othman, Ahmed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027977/
https://www.ncbi.nlm.nih.gov/pubmed/31594037
http://dx.doi.org/10.1002/cpt.1668

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027977/
https://www.ncbi.nlm.nih.gov/pubmed/31594037
http://dx.doi.org/10.1002/cpt.1668

Ejemplares similares